Technical / White Paper

NXT LVL Clinical Trials. Direct-to-Patient: Your Top 10 Q&A.

12 SEP 2016 Monday

Format: PDF file | Document type: Technical / White Paper | Promoted Content

This Technical / White Paper has been written by World Courier , and any views and opinions expressed do not necessarily reflect those of www.biopharma-reporter.com

Take your clinical trials to the next level. The direct-to-patient (DtP) model solves two of the largest issues plaguing clinical trials: patient recruitment and retention. This article answers the top 10 questions asked about DtP.

Download the Q&A to find answers to the following and more:

What are the major differences between DtP and traditional clinical trials?
How does a DtP model benefit patients?
How does a DtP model benefit trial sponsors?
What are the challenges and subsequent risks?

Latest content from World Courier

Content provided by World Courier

Cell and gene therapies: Commercialization considerations

Moving cell and gene therapies from a clinical to commercial setting requires a transformation of the traditional supply chain model. World Courier explores the considerations for therapy owners.